Introduction
Cell death by apoptosis plays an important role in the regulation of various physiological or pathological conditions and has also been implied to mediate therapy-induced cytotoxicity, e.g. in response to cytotoxic drug treatment or g-irradiation (Peter and Krammer, 1998; Grith and Lynch, 1998; Kaufmann and Earnshaw, 2000; Debatin, 1997; Friesen et al., 1996; Fulda et al., 1997 Fulda et al., , 1998 . Apoptosis pathways may be initiated through dierent entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway) resulting in activation of eector caspases (Peter and Krammer, 1998; Grith and Lynch, 1998; Kaufmann and Earnshaw, 2000; Debatin, 1997) . Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO1/Fas) results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain (FADD) and caspase-8 (Peter and Krammer, 1998; Sprick et al., 2000) . Upon recruitment caspase-8 becomes activated and initiates apoptosis by direct cleavage of downstream eector caspases (Peter and Krammer, 1998; Thornberry and Lazebnik, 1998) . A second pathway is initiated at the mitochondrial level (Kroemer and Reed, 2000) . Apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), caspase-2 or caspase-9 are released from mitochondria into the cytosol triggering caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex (Kroemer and Reed, 2000; Susin et al., 1999) . In these cells, caspase-8 is activated downstream of mitochondria promoting further cleavage of eector caspases. Signals originating from the CD95 receptor may be linked to mitochondria by Bid, a BH3 domain containing protein of the Bcl-2 family which assumes cytochrome-c-releasing activity upon cleavage by caspase-8 thereby initiating a mitochondrial ampli®cation loop (Kroemer and Reed, 2000) . Studies from caspase-8 knock-out mice indicate that caspase-8 plays a necessary and non-redundant role in various forms of cell death (Los et al., 1999) .
Resistance of many tumors such as neuroblastoma to current treatment protocols still remains a major concern in cancer therapy. Deregulated apoptosis programs may contribute to tumor progression and treatment resistance (Debatin, 1997; Friesen et al., 1997; Tschopp et al., 1998; Kroemer, 1997; Deveraux and Reed, 1999) . Thus, the identi®cation of molecular defect(s) in apoptosis signaling may be crucial to develop novel strategies to target resistance. We previously reported that increased recruitment and activation of caspase-8 through downregulation of FLICE-inhibitory protein (FLIP) by metabolic inhibitors sensitized for CD95-induced apoptosis (Fulda et al., 2000) . Recent studies indicated that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. Caspase-8 expression was frequently impaired by hypermethylation in various resistant tumor cells, and re-expression of caspase-8 by demethylation or by caspase-8 gene transfer sensitized for death receptor-or drug-induced apoptosis (Teitz et al., 2000; Fulda et al., 2001) . However, the clinical use of metabolic inhibitors or demethylating agents has been limited because of toxic side eects.
In search for a more physiologically relevant sensitizing agent to overcome resistance we investigated the ability of IFNg to modulate apoptosis sensitivity in the present study. Interferons (IFN's) are a family of cytokines with antiviral, immunomodulatory, antiproliferative and dierentiation-promoting eects (Stark et al., 1998; Boehm et al., 1997) . In addition, IFN's have been shown to enhance antitumor activity of chemotherapeutic agents and cell death following CD95 triggering (Darnell et al., 1994) . IFN's exert their pleiotropic biological eects in part by transcriptional regulation of gene expression, e.g. through activation of signal transducers and activators of transcription (STATs) (Darnell et al., 1994; Taniguchi et al., 1997; Bromberg and Darnell, 2000) . IFNg can increase expression of several apoptosis-related molecules in a stimulus-and cell type-speci®c manner, e.g. death receptors such as CD95, dierent members of the Bcl-2 family or caspases such as caspase-1 (Ossina et al., 1997; Ruiz-Ruiz et al., 2000; Iwase et al., 1999; Lutz et al., 1998) . However, the mechanism(s) of IFNg-mediated modulation of cellular susceptibility to apoptosis has not been fully elucidated (Ossina et al., 1997; Ruiz-Ruiz et al., 2000; Iwase et al., 1999; Lutz et al., 1998) . Here, we report that treatment with IFNg sensitized various resistant tumor cell lines derived from neuroblastoma, Ewing tumor or medulloblastoma with absent or low caspase-8 expression for apoptosis induced by death receptor ligation or cytotoxic drugs. IFNg-mediated sensitization involved upregulation of caspase-8 expression in a Stat1/IRF1 dependent manner. Since recent evidence suggests that inactivation of caspase-8 expression may be an important mechanism of resistance in some tumors, these ®ndings indicate that the combination of IFNg with TRAIL or cytotoxic drugs might be an eective strategy to overcome resistance and to restore sensitivity of tumor cells for chemotherapy-or death receptor-induced apoptosis.
Results
Recent studies indicated that demethylating agents could sensitize resistant tumor cells with hypermethylation of the caspase-8 gene for apoptosis induction (Teitz et al., 2000; Fulda et al., 2001) . To ®nd a more physiologically relevant sensitizing agent, we investigated the ability of IFNg to modulate apoptosis sensitivity in the present study.
Sensitization for death receptor-or drug-induced apoptosis by IFNg
Treatment with TRAIL or IFNg alone only induced minimal apoptosis in dierent tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, whereas combined treatment with TRAIL and IFNg cooperated to trigger apoptosis (Figure 1a ). Sensitization for apoptosis by IFNg occurred in a dosedependent manner (Figure 1b) . To exclude that the apoptosis promoting activity of IFNg was restricted to TRAIL, we tested the eect of IFNg in dierent treatment combinations. Similarly, combined treatment of IFNg with APO1, TNFa or dierent cytotoxic drugs, e.g. doxorubicin, cisplatinum or VP-16 markedly increased apoptosis compared to either treatment alone ( Figure 1c ). We also analysed the eect of IFNg on long term survival using a modi®ed clonogenic assay. Cells were seeded at single cell density followed by treatment with IFNg and/or TRAIL for 7 days. Combined treatment with IFNg and TRAIL strongly reduced colony numbers compared to single agent treatment or untreated controls (Figure 1d ). This indicates that IFNg also promoted the eect of TRAIL treatment on long term survival of tumor cells.
Effect of IFNg on expression of pro-or antiapoptotic molecules
To gain insight into the mechanism(s) of IFNgmediated sensitization, we monitored by Western blot analysis the expression of several key regulators of apoptosis. IFNg strongly increased caspase-8 levels in CHP-126 neuroblastoma cells with very low constitutive expression of caspase-8 (Figure 2a ). IFNg also enhanced protein expression of caspase-1, DAP3, CD95 and p21, whereas no signi®cant eect on expression of other caspases, molecules of the death receptor pathway, Bcl-2 family proteins or inhibitor of apoptosis proteins (IAP's) was seen (Figure 2a) . Also by¯ow cytometry, CD95 surface expression was found to be enhanced by IFNg, whereas no signi®cant increase in TNF-RI or TRAIL-R1-R4 expression was seen (data not shown).
To exclude that the observed eect of IFNg on caspase-8 expression was restricted to a particular cell line, we then analysed several dierent tumor cell lines, which we previously found to have absent or low caspase-8 expression (Fulda et al., 2001) . Similarly, treatment with IFNg resulted in increased expression of caspase-8 protein in dierent tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma (Figure 2b ). These ®ndings suggest that IFNg may be eective in increasing caspase-8 expression in several dierent tumor cell types.
Involvement of caspase-8 in IFNg-mediated sensitization for apoptosis
To determine the signi®cance of caspase-8 induction for mediating sensitization by IFNg, we used the relatively speci®c caspase-8 inhibitor zIETD.fmk (Nicholson, 1999) . The apoptosis-promoting eect of IFNg for TRAIL or doxorubicin-induced apoptosis was markedly reduced in the presence of zIETD.fmk in dierent cell types (Figure 3a) . Also, we made use of caspase-8 mutant Jurkat cells (Juo et al., 1998) . In wild-type Jurkat cells, expression of caspase-8, which was already detected in untreated cells, was further enhanced upon IFNg treatment, in good correlation with sensitization for apoptosis by IFNg in response to treatment with TRAIL or APO1 in these cells ( Figure  3b, c) . In contrast, no increase in caspase-8 levels and no sensitization for apoptosis by IFNg was found in caspase-8 mutant Jurkat cells (Figure 3b, c) . Moroever, we analysed caspase-8 function by monitoring activation of apoptosis pathways. Combination treatment with TRAIL and IFNg resulted in cleavage of caspase-8, caspase-9, caspase-7 and Bid as determined by the appearance of the caspase-8 active subunit p18 and the decrease of caspase-9 or caspase-7 proenzyme or fulllength Bid, while no activation of caspases was found upon single agent treatment (Figure 3d ). This indicates that restoration of caspase-8 expression by IFNg in cells with absent caspase-8 expression also restored defective apoptosis signaling.
Cooperation of IFNg and TRAIL to trigger the mitochondrial pathway
The above ®ndings showing that IFNg promoted cleavage of caspase-9 upon TRAIL receptor triggering indicated that IFNg facilitated a mitochondria-operated pathway of apoptosis. This prompted us to further investigate the mitochondrial pathway. While single agent treatment using IFNg, TRAIL, APO1 or doxorubicin triggered only minimal loss of mitochondrial potential, the combination of IFNg with TRAIL, APO1 or doxorubicin markedly enhanced loss of mitochondrial potential (Figure 4a ). IFNg and TRAIL also cooperated to trigger release of cytochrome c from mitochondria into the cytosol (Figure 4b ). The promoting eect of IFNg on loss of MMP and cytochrome c release upon death receptor triggering was strongly reduced in the presence of the broad range caspase inhibitor zVAD.fmk or the relatively caspase-8 speci®c inhibitor zIETD.fmk (Figure 4a, b) . These results suggest that IFNg exerted its eect, at least in part, at a level upstream of mitochondria.
Effect of IFNg on the methylation status of the caspase-8 gene
To gain insight into the mechanism(s) of caspase-8 upregulation by IFNg, we analysed whether the increase in caspase-8 protein was regulated at the transcriptional level. Treatment with IFNg resulted in increased expression of both caspase-8 mRNA and protein ( Figure 5a ) indicating that caspase-8 expression was transcriptionally regulated by IFNg.
Epigenetic changes such as DNA methylation may result in gene inactivation in the absence of genetic alterations (Jones, 1985; Herman and Baylin, 2000) . Since we recently found inactivation of caspase-8 by hypermethylation of the caspase-8 gene in several neuroectodermal tumor cells (Fulda et al., 2001) , we asked whether IFNg-induced upregulation of caspase-8 expression was the result of alterations in the DNA methylation status of the caspase-8 gene. To address this question we performed methylation-speci®c PCR using primers corresponding to a CpG-rich part of the 5'¯anking region of caspase-8 (Teitz et al., 2000; Grenet et al., 1999) . Treatment with IFNg had no eect on the methylation status of the caspase-8 gene ( Figure 5b ). In contrast, treatment with dAzaC resulted in partial demethylation of the caspase-8 gene, which was not further enhanced by the addition of IFNg ( Figure 5b ). Also, combined treatment with IFNg and dAzaC did not further increase caspase-8 expression compared to either treatment alone ( Figure 5c ). In addition, treatment with IFNg did not signi®cantly alter the expression of DNA methyltransferases (DNMT) involved in DNA methylation such as DNMT1, DNMT3a or DNMT3b (Figure 5d ) (Hendrich and Bird, 2000) . These ®ndings suggest that IFNg-mediated modulation of apoptosis sensitivity was not the result of an altered methylation status of regulatory sequences of the caspase-8 gene.
IFNg-induced caspase-8 expression and sensitization for apoptosis is mediated by the Stat pathway
Since the Stat pathway has been reported to regulate transcription of IFNg-inducible genes (Darnell et al., 1994; Bromberg and Darnell, 2000) , we then analysed Stat1 phosphorylation in response to IFNg. Stimulation with IFNg resulted in Stat1 phosphorylation as detected by an antibody speci®c for Stat1 phosphosphorylated at tyrosine 701 ( Figure 6a ). Re-hybridization with a Stat1 antibody showed similar yields of Stat1 proteins in untreated and IFNg-treated cells ( Figure 6a ). A direct connection between the sensitizing eect of IFNg and activation of Stat1 was tested using the Stat1-de®cient cell line U3A (McKendry et al., 1991) . In Stat1-de®cient U3A cells, IFNg was unable to further upregulate caspase-8, which was expressed at basal levels in these cells (Figure 6b ). Also, IFNg did not sensitize Stat1-de®cient U3A cells for treatment with TRAIL or APO1 (Figure 6c ). However, complementation of Stat1-de®cient U3A cells with wild-type Stat1 restored the ability of IFNg to upregulate caspase-8 expression, which was also found in the parental cell line 2fTGH that expresses wild-type Stat1 (Figure 6b ). Accordingly, IFNg enhanced TRAIL-or APO1-induced apoptosis in U3A Stat1 cells, in which Stat1 had been reintroduced, as well as in the parental 2fTGH cells ( Figure  6c ). To further investigate whether Stat1 activation , ET2 .1, 6647, RDES), neuroblastoma (CHP-126, Kelly, SH-SY5Y) or medulloblastoma (D283Med) cells were treated for 72 h with 0 ± 100 ng/ml TRAIL in the absence (white bars) or presence (black bars) of 1000 U/ml IFNg. In (b) CADO Ewing tumor, CHP-126 neuroblastoma or D283Med medulloblastoma cells were treated for 72 h with 0 ± 100 ng/ml TRAIL and 0 ± 1000 U/ml IFNg. Apoptosis was determined by FACS analysis of propidium iodide stained DNA content. Percentage of speci®c apoptosis was calculated as follows: 1006[experimental apoptosis (%) 7 spontaneous apoptosis (%)/100% 7 spontaneous apoptosis (%)]. Spontaneous apoptosis was 511%. Mean and s.d. of triplicates are shown, similar results were obtained in three independent experiments. (c) Eect of IFNg on APO1-, TNFa-or drug-induced apoptosis. CADO Ewing tumor, CHP-126 neuroblastoma or D283Med medulloblastoma cells were treated for 72 h with 0.1 mg/ml anti-APO1 monoclonal antibody, 100 ng/ ml TNFa, 0.03 mg/ml doxorubicin, 0.3 mg/ml cisplatinum or 0.3 mg/ml VP-16 in the absence (white bars) or presence (black bars) of 1000 U/ml IFNg. Apoptosis was determined as described in (a (Figure 7d ). Taken together, these results strongly suggest that Stat1 and IRF1 were involved in induction of caspase-8 and sensitization for apoptosis in response to IFNg.
Discussion
Despite aggressive therapy, resistance of many tumors to current treatment protocols still remains a major concern in cancer therapy. Since resistance to anticancer therapy may be caused by a defective cell death program, the identi®cation of molecular defect(s) in apoptosis signaling may be crucial to develop novel strategies that increase the susceptibility of resistant tumor cells for apoptosis induction. Recent evidence indicates that tumor cells often evade apoptosis by dysregulating components of the CD95 DISC, e.g. decreased caspase-8 or increased FLIP levels (Tschopp et al., 1998; Teitz et al., 2000) . Thus, sensitization for apoptosis may be achieved by metabolic inhibitors through downregulation of FLIP or by demethylating a b Figure 4 Eect of IFNg on TRAIL, APO1 or docorubicin-induced mitochondrial perturbations. (a) Eect of IFNg on TRAIL, APO1 or doxorubicin-induced loss of Dc m CHP-126 neuroblastoma cells were treated for 24 h with 100 ng/ml TRAIL and/or 0.1 mg/ml anti-APO1 monoclonal antibody, 0.03 mg/ml doxorubicin, 1000 U/ml IFNg, 50 mM zVAD.fmk, 50 mM zIETD.fmk. DC m was determined by staining cells with the potential-sensitive¯uorochrome DiOC 6 (3). Mean and s.d. of triplicates are shown, similar results were obtained in three independent experiments. (b) Eect of IFNg on TRAIL-induced cytochrome c release. CHP-126 neuroblastoma cells were treated for 48 h with 100 ng/ml TRAIL and/or 1000 U/ml IFNg, 50 mM zVAD.fmk. Mitochondrial (M) or cytosolic (C) extracts were prepared as described in Materials and methods. Western blot analysis for cytochrome c or COX4 was performed as described above using mouse anti-cytochrome c or mouse anti-COX4 monoclonal antibody and ECL agents in tumor cells with hypermethylation of the caspase-8 gene (Teitz et al., 2000; Fulda et al., 2000) . However, the clinical use of metabolic inhibitors or demethylating agents has been limited because of toxic side eects. Therefore, to ®nd a more physiological sensitizing agent to overcome resistance, we investigated the ability of IFNg to modulate apoptosis sensitivity. Here, we report that IFNg sensitizes dierent resistant tumor cell lines with absent or low caspase-8 expression for apoptosis induced by death inducing ligands or cytotoxic drugs by upregulation of caspase-8 expression through a Stat1/IRF1 dependent pathway. This conclusion is based on a number of independent pieces of evidence.
First, IFNg-mediated sensitization for apoptosis was strongly inhibited in the presence of the relatively speci®c caspase-8 inhibitor zIETD.fmk. Second, caspase-8 mutant Jurkat cells remained completely resistant to the IFNg-mediated sensitization eect, whereas in wild type Jurkat cells IFNg increased caspase-8 levels and sensitized for apoptosis in response to TRAIL or APO1. Third, induction of caspase-8 expression by IFNg resulted in activation of caspase-8 upon TRAIL treatment leading to activation of downstream apoptosis pathways with cleavage of Bid, caspase-9 and caspase-7. This indicates that restoration of caspase-8 expression by IFNg in cells with absent or low caspase-8 also restored defective apoptosis signaling. Caspase-8 has been implied to mediate apoptosis upon stimulation of both the death receptor and/or the mitochondrial pathway (Peter and Krammer, 1998; Kaufmann and Earnshaw, 2000) consistent with our ®ndings that upregulation of caspase-8 by IFNg sensitized for death receptor-and drug-induced apoptosis. Thus, increased caspase-8 levels might promote eective DISC formation upon death receptor triggering and auto-processing of caspase-8 by induced proximity (Salvesen and Dixit, 1999) . In addition, active caspase-8 might initiate a mitochondrial ampli®cation loop by cleaving Bid resulting in increased cytochrome c release and activation of eector caspases through formation of the cytochrome c/Apaf-1/ caspase-9 apoptosome complex (Kroemer and Reed, 2000; Kaufmann and Earnshaw, 2000 ). An increase in chemosensitivity upon upregulation of caspase-8 from 5 ± 20% to 20 ± 50% may be clinically meaningful, since it may critically aect the time required for execution of the death program (Tang et al., 2000) . However, the eect of IFNg on apoptosis modulation may also involve other mechanisms than upregulation of caspase-8, since IFNg also increased expression of CD95, DAP3 or p21, which have all been implied in promoting apoptosis (Stark et al., 1998) . We also observed an increase in caspase-1 protein by IFNg, however, recent evidence suggests that caspase-1 may not play a prominant role in death receptor induced apoptosis in many cell types (Los et al., 1999) .
Although there are previous reports that IFNg enhanced caspase-8 expression in some tumor cells, e.g. breast carcinoma or colon carcinoma cells, the underlying mechanism(s) have not yet been elucidated (Ruiz-Ruiz et al., 2000) . Here, we present evidence that upregulation of caspase-8 and sensitization for apoptosis by IFNg is mediated through the Stat1/IRF1 pathway. First, IFNg induced Stat1 phosphorylation Parental (2fTGH), Stat1-de®cient (U3A) or Stat1-transfected U3A cells (U3AStat1) were left untreated or treated for 48 h with 1000 U/ml IFNg. Expression of caspase-8 protein was analyzed by Western blot as described above. Expression of b-actin was used to control for equal gel loading. (c) Eect of Stat1 on IFNg-mediated sensitization for apoptosis. Parental (2fTGH), Stat1-de®cient (U3A) or Stat1-transfected U3A cells (U3AStat1) were treated for 72 h with 100 ng/ml TRAIL, 0.1 mg/ml APO1 and/or 1000 U/ml IFNg. Apoptosis was determined as described in Figure 1a . Twenty-four hours after transfection cells were treated for 48 h with 100 ng/ml TRAIL, 0.1 mg/ml APO1 or 0.03 mg/ml doxorubicin. Apoptosis was analysed by¯ow cytometry in transfected cells which were identi®ed by cotransfection with pDsRed1-N1 (50 ± 65% transfection ecacy) 1999), our ®ndings indicate that transcriptional regulation of caspase-8 expression involved Stat1 activity. Stat1 probably signals caspase-8 expression through enhanced transcription of IRF1, which is known as a target gene of Stat1, since overexpression of a dominant negative Stat1 mutant reduced induction of IRF1 expression by IFNg. Also, caspase-8 expression may be regulated by Stat1 independently of IRF1 or by IRF1 in a Stat1-independent manner. Importantly, IFNg upregulated caspase-8 even in tumor cells with absent or very low caspase-8 expression due to hypermethylation of the caspase-8 gene. In contrast, previous reports only demonstrated an additional increase of caspase-8 levels by IFNg in cells which already expressed caspase-8 (Ruiz- Ruiz et al., 2000) . However, we found no eect of IFNg on the methylation status of the caspase-8 gene indicating that IFNg also enhanced transcription of genes with hypermethylation of gene regulatory sequences. To our knowledge, activation of a methylated promotor has not previously been described (Rountree et al., 2001 ) and might be due to incomplete hypermethylation of gene regulatory sequences of the caspase-8 gene. Also, the observed increase in caspase-8 mRNA expression might be post-transcriptionally regulated with unaltered rate of transciptional initiation.
Since recent data indicate that caspase-8 is frequently inactivated by hypermethylation in various resistant tumor cells (Teitz et al., 2000) , strategies to restore caspase-8 expression in cells with de®cient caspase-8 expression, e.g. IFNg, may therefore prove to be critical to overcome resistance. In addition, our ®ndings for the ®rst time demonstrate that IFNg also sensitized cells for apoptosis induced by TRAIL in addition to CD95, TNFa or cytotoxic drugs. This might have important clinical implications, since sensitizing regimens using IFNg together with TRAIL, which is considered to be toxic only for tumor cells, might be useful for therapeutic strategies, in contrast to CD95 ligand or TNFa which cause severe toxic eects upon systemic administration (Grith and Lynch, 1998; Peter and Krammer, 1998) . Moreover, our ®ndings were not restricted to one particular tumor, but were similarly found in a number of dierent tumor cell types.
While our in vitro studies already demonstrated a signi®cant antitumor eect of IFNg in combination with death-inducing ligands or cytotoxic drugs, an even more pronounced eect might occur in vivo because possible additional in vivo eects of IFNg (Wadler and Schwartz, 1990) . IFNg might have a protective eect on normal host tissues, an eect on drug-metabolizing enzymes or on the host immune response including augmentation of antibody-dependent cell mediated cytotoxicity and NK cell activity (Wadler and Schwartz, 1990) . Since neuroblastoma cells frequently do not express class I or class II MHC molecules and are therefore poorly immunogenic (Maris and Matthay, 1999) , IFNg may maximize the antitumor immune response to neuroblastoma cells by increasing their immunogenicity through upregulation of class I MHC molecules which we observed upon treatment with IFNg (data not shown). In addition, IFNg has been reported to promote dierentiation of neuroblastoma cells and is included in dierentiation-based protocols (Montaldo et al., 1994) . Interestingly, a potential role of IRF1 as a tumor suppressor gene has been implied in leukemia and other forms of cancer (Stark et al., 1998) . However, preliminary results of few clinical trials indicated a rather limited cytotoxic activity of IFNg in combination with chemotherapy (Wadler and Schwartz, 1990) , although our ®ndings and previous reports demonstrated signi®cant cooperation of IFNg and anticancer drugs or cytotoxic ligands in vitro, which may, at least in part, re¯ect the additional levels of complexity in signaling pathways of apoptosis and transcriptional regulation in vivo.
Thus, by demonstrating that IFNg sensitized various tumor cells for apoptosis upon death receptor ligation and, importantly, also upon treatment with cytotoxic drugs through upregulation of caspase-8 via activation of the Stat1/IRF1 pathway, our ®ndings provide new insights into mechanisms that regulate sensitivity and resistance. Recent evidence suggests that dysregulation of DISC components of death receptors such as CD95 by hypermethylation of the caspase-8 gene or overexpression of FLIP, could be a common strategy used by tumor cells to escape apoptosis induced by cytotoxic therapies resulting in resistance (Tschopp et al., 1998; Teitz et al., 2000) . In light of these studies, our ®ndings may have important implications for cancer therapy. Current attempts to improve cancer survival depend on strategies to target tumor cell resistance and on the development of novel treatment modalities, e.g. immunotherapy, gene therapy or cytotoxic cytokines such as TRAIL. Because the potential success of these approaches largely depends on intact death receptor pathways in target cells, strategies to restore caspase-8 expression in cells with de®cient caspase-8 expression, e.g. by IFNg, may prove to be a useful complementary tool to the treatment of cancer.
Materials and methods

Cell culture
Ewing tumor (CADO-ES-1 (CADO), RDES, 6647, STA-ET-2.1 (ET2.1) (50)), neuroblastoma (KAN, Kelly, IMR5, SH-SY5Y, CHP-126), medulloblastoma (D283Med), U3A, U3AStat1, 2fTGH ®broblast or caspase-8 mutant Jurkat T cell leukemia cells were maintained in culture as previously described Van Valen et al., 1999; McKendry et al., 1991; Juo et al., 1998) . Cells (0.5610 5 ) per ml were cultured in 24-well-plates for determination of apoptosis or in 75 cm 2¯a sks (Falcon, Heidelberg, Germany) for protein isolation.
Determination of apoptosis
Cells were incubated with mouse anti-APO1 IgG3 monoclonal antibody, recombinant human TRAIL (PeproTech Inc., Rocky Hill, NJ, USA), TNFa (Calbiochem, Bad Soden, Germany), doxorubicin (Amersham Pharmacia, Freiburg, Germany), cisplatinum (Sigma, Deisenhofen, Germany), etoposide (Bristol Myers, Munich, Germany), benzyloxycarbonyl-Val-Ala-Asp-¯uoromethylketone (zVAD.fmk; Bachem, Heidelberg, Germany) or benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-¯uoromethylketone (zIETD.fmk; Bachem), cycloheximide (CHX, Sigma), IFNg (Biochrom, Berlin, Germany) or 5-Aza-2'-deoxycytidine (dAzaC; Sigma). Quanti®cation of DNA fragmentation was performed by¯uorescence-activated cell-sorting (FACS) analysis of propidium iodide stained nuclei as previously described . Percentage of speci®c apoptosis was calculated as follows: 1006[experimental apoptosis (%) 7 spontaneous apoptosis (%) / 100% 7 spontaneous apoptosis (%)].
Clonogenicity assay
Cells (10 3 ) were seeded in a 6-well plate and treated for 7 days with 1000 U/ml IFNg and/or 100 ng/ml TRAIL. Clonogenic survival was determined by staining colonies using crystal violet and visualized by digital camera.
Western blot analysis and immunoprecipitation
Western blot analysis was performed as previously described using rabbit anti-caspase-1 polyclonal antibody (1 : 1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-caspase-2 monoclonal antibody (1 : 1000, Transduction Laboratories, Lexington, KY, USA), mouse anti-caspase-3 monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-caspase-7 monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anticaspase-8 monoclonal antibody C15 (1 : 10 dilution of hybridoma supernatant) (Scadi et al., 1997) , rabbit anticaspase-9 polyclonal antibody (1 : 1000, PharMingen, San Diego, CA, USA), rabbit anti-caspase-10 polyclonal antibody (1 : 1000, PharMingen), rabbit anti-cIAP2 polyclonal antibody (1 : 1000, Santa Cruz Biotechnology), goat anti-cIAP1 polyclonal antibody (1 : 1000, Santa Cruz Biotechnology), rabbit anti-survivin polyclonal antibody (1 : 100, R&D Systems, Wiesbaden-Nordenstadt, Germany), rabbit antiBax polyclonal antibody (1 : 1000, Upstate Biotechnology, Lake Placid, NY, USA), goat anti-Bak polyclonal antibody (1 : 1000, Santa Cruz Biotechnology), rabbit anti-Bid polyclonal antibody (1 : 100, Trevigen, Gaithersburg, MD, USA), mouse anti-Mcl1 monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-Bcl-2 monoclonal antibody (1 : 1000, Santa Cruz Biotechnology), rabbit anti-Bcl-X L/S polyclonal antibody (1 : 1000, Santa Cruz Biotechnology), mouse anti-HSP70 monoclonal antibody (1 : 1000, Stressgen Biotechnologies Corp., Victoria, Canada), mouse anti-FADD monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-TRAIL monoclonal antibody (1 : 2500, PharMingen), rabbit anti-FLIP polyclonal antibody (1 : 1000, PharMingen), mouse anti-DAP3 monoclonal antibody (1 : 1000, Transduction Laboratories), rabbit anti-TRAIL-R1 polyclonal antibody (1 : 2000, PharMingen), mouse anti-TRAIL-R2 monoclonal antibody (1 : 100, Oncogene Research Products, Boston, MA, USA), mouse anti-CD95 monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-CD95L monoclonal antibody (1 : 250, PharMingen), mouse anti-XIAP monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-p53 monoclonal antibody (1 : 1000, Transduction Laboratories), rabbit anti-p21 polyclonal antibody (1 : 1000, Santa Cruz Biotechnology), mouse anticytochrome c monoclonal antibody (1 : 5000, PharMingen), mouse anti-COX4 monoclonal antibody (1 : 1000, Clontech Laboratories, Inc., Palo Alto, CA, USA), mouse anti-Stat1 monoclonal antibody (1 : 1000, Transduction Laboratories), rabbit anti-phospho-Stat1 (Y701) polyclonal antibody (1 : 1000, Upstate Biotechnology), or mouse anti-b-actin monoclonal antibody (1 : 5000, Sigma) followed by goat anti-mouse IgG or goat anti-rabbit IgG (1 : 5000, Santa Cruz Biotechnology). Enhanced chemiluminescence (ECL, Amersham Pharmacia) was used for detection. Immunoprecipitation of Stat1 was performed as previously described using mouse anti-Stat1 monoclonal antibody (10 mg/ml, Transduction Laboratories) and protein A/G plus agarose (1 mg/ml, Transduction Laboratories).
RT ± PCR and methylation-specific PCR RT ± PCR was performed as previously described . Genomic DNA was isolated using the Qiagen blood and cell culture DNA kit (Qiagen, Hilden, Germany). Methylation-speci®c PCR was performed as previously described (Herman et al., 1996) using primers corresponding to a CpG-rich region of the 5'¯anking region of the caspase-8 gene (Teitz et al., 2000; Grenet et al., 1999) . Genomic DNA not treated with bisul®te (unmodi®ed) was not ampli®ed with either the methylated or unmethylated primers, peripheral blood lymphocytes were used as positive control for unmethylated caspase-8 and in vitro methylated DNA as positive control for methylated DNA (data not shown). The following primer sequences were used (Interactiva Biotechnologie GmbH, Ulm, Germany): caspase-8 unmethylatedspeci®c 5'-TAGGGGAATTTGGAGATTGTGA-3' and 5'-CCATATATATCTACTTCAAAACAA-3', caspase-8 methylated-speci®c 5'-TAGGGGATTCGGACATTGCGA-3' and 5'-CGTATATCTACATTCGAAACGA-3', caspase-8 5'-CA-GCATTAGGGACAGGAATC-3' and 5'-CAGTTATTCAC-AGTGGCCAT-3', DNMT1 5'-GATCGAATTCATGCCGG-CGCGTACCGCCCCAG-3' and 5'-ATGGTGGTTTGCCT-GGTGC-3', DNMT3a 5'-GGGGACGTCCGCAGCGTCA-CA-3' and 5'-CAGGGTTGGACTCGAGAAATCGC-3', DNMT3b 5'-CCTGCTGAATTACTCACGCCCC-3' and 5'-GTCTGTGTAGTGCACAGGAAAGCC-3', IRF1 5'-CATC-CCAGTGGAAGTTGTGCC-3' and 5'-CAGAAGTCCAGC-TTCTCTGCACC-3', ISGF3g 5'-AGGACTTCCGGGAGG-ACCAG-3' and 5'-GGTGCATTCCAGGAGATGGG-3'. Expression of b-actin (Stratagene, Heidelberg, Germany) was used as standard for RNA integrity and equal gel loading. Speci®city of PCR-reaction products was controlled by DNA sequencing. PCR-reaction products were run on a 1.5% agarose gel, stained with ethidium bromide and visualized by UV illumination.
Transfection experiments
CHP-126 neuroblastoma cells were transfected with expression plasmid pCR3.1 containing IRF1 cDNA (Iwase et al., 1997;  In Vitrogen, Groningen, The Netherlands), or pRcCMV containing Stat1 Y701F or Stat1b (Bromberg and Darnell, 2000; In Vitrogen) together with pDsRed1-N1 plasmid (Clontech Laboratories) to identify transfected cells by¯ow cytometry (50 ± 65% transfection ecacy) using lipofectamine transfection reagent (Life Technologies, Inc., Eggenstein, Germany).
Preparation of mitochondria or cytosolic extracts
Preparation of mitochondria or cytosolic extracts was performed using the ApoAlert cell fractionation kit (Clontech Laboratories) according to the manufacturer's instructions.
Proteins were separated by 10 ± 20% SDS ± PAGE and Western blot analysis was performed as described above.
Assessment of mitochondrial transmembrane potential
The cationic lipophilic¯uorochrome 3,3'-dihexyloxacarbocyanide iodide (DiOC 6 (3)) (460 ng/ml, Molecular Probes, Eugene, OR, USA) was used to measure the mitochondrial transmembrane potential (DC m ). Cells were incubated for 15 min at 378C in the presence of the¯uorochrome, washed in PBS/1% FCS and immediately analysed by¯ow cytometry (FACScan, Becton Dickinson). DiOC 6 (3) was recorded in uorescence 1. As a control, cells were treated with the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (200 mM; Sigma).
